- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 4.23 Compensation Policy for Executive Officers
- 4.24 Compensation Policy for Directors
- 4.25 Kamada LTD. 2011 Israeli Share Award Plan
- 4.37 Amended and Restated Manufacturing Services Agreement Dated As of September 28, 2017, by and Between Emergent Biosolutions, Inc. and Aptevo Therapeutics Inc. (Assumed by Kamada LTD.)
- 4.38 Contract Manufacturing, Services and Supply Agreement Dated November 29, 2022, by and Between Kamada LTD. and Prothya Biosolutions Belgium
- 4.39 Supplemental Letter Agreement Dated As of July 4, 2022, by and Between Kamada LTD. and Tuteur S.a.c.i.f.i.a.
- 4.40 2ND Amendment to the Distribution Agreement, Dated As of February 22, 2023, by and Between Kamada LTD. and Tuteur S.a.c.i.f.i.a.
- 8.1 Subsidiaries of the Registrant
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 15.1 Consent of Ernst & Young Global, Independent Registered Public Accounting Firm
- Download Excel data file
- View Excel data file
Exhibit 13.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Kamada Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Amir London, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: | March 15, 2023 |
/s/ Amir London | |
Amir London | |
Chief Executive Officer |
In connection with the Annual Report of Kamada Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Chaime Orlev, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: | March 15, 2023 |
/s/ Chaime Orlev | |
Chaime Orlev | |
Chief Financial Officer |